JOP20210331A1 - مُعَدِّلات مُستقبِل نمدا (nmda) - Google Patents

مُعَدِّلات مُستقبِل نمدا (nmda)

Info

Publication number
JOP20210331A1
JOP20210331A1 JOP/2021/0331A JOP20210331A JOP20210331A1 JO P20210331 A1 JOP20210331 A1 JO P20210331A1 JO P20210331 A JOP20210331 A JO P20210331A JO P20210331 A1 JOP20210331 A1 JO P20210331A1
Authority
JO
Jordan
Prior art keywords
nmda receptor
receptor modulators
compounds
directed
inventions
Prior art date
Application number
JOP/2021/0331A
Other languages
English (en)
Inventor
Mauro Marigo
Erhad Ascic
Laurent David
John Paul Kilburn
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of JOP20210331A1 publication Critical patent/JOP20210331A1/ar

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B62—LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
    • B62D—MOTOR VEHICLES; TRAILERS
    • B62D15/00—Steering not otherwise provided for
    • B62D15/02—Steering position indicators ; Steering position determination; Steering aids
    • B62D15/027—Parking aids, e.g. instruction means
    • B62D15/0285—Parking performed automatically
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W30/00—Purposes of road vehicle drive control systems not related to the control of a particular sub-unit, e.g. of systems using conjoint control of vehicle sub-units
    • B60W30/06—Automatic manoeuvring for parking
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W60/00—Drive control systems specially adapted for autonomous road vehicles
    • B60W60/001—Planning or execution of driving tasks
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W2510/00—Input parameters relating to a particular sub-units
    • B60W2510/20—Steering systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Automation & Control Theory (AREA)
  • Epidemiology (AREA)
  • Combustion & Propulsion (AREA)
  • Human Computer Interaction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق هذا الاختراع بإعداد مُعَدِّلات جديدة لمستقبل نمدا (NMDA). وُجِّهَت مظاهر منفصلة لهذا الاختراع إلى تركيبات صيدلية تتضمن المركبات المذكورة واستخدامات المركبات في علاج الاضطرابات العصبية والاضطرابات النفسية العصبية مثل الاكتئاب.
JOP/2021/0331A 2019-07-03 2021-12-14 مُعَدِّلات مُستقبِل نمدا (nmda) JOP20210331A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201900821 2019-07-03
PCT/EP2020/068522 WO2021001423A1 (en) 2019-07-03 2020-07-01 Modulators of the nmda receptor

Publications (1)

Publication Number Publication Date
JOP20210331A1 true JOP20210331A1 (ar) 2021-12-14

Family

ID=74065626

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0331A JOP20210331A1 (ar) 2019-07-03 2021-12-14 مُعَدِّلات مُستقبِل نمدا (nmda)

Country Status (21)

Country Link
US (1) US11466027B2 (ar)
EP (1) EP3994141A1 (ar)
JP (1) JP2022539197A (ar)
KR (1) KR20220029568A (ar)
CN (1) CN114008054A (ar)
AR (1) AR119340A1 (ar)
AU (1) AU2020299992A1 (ar)
BR (1) BR112021003928A2 (ar)
CA (1) CA3144304A1 (ar)
CL (1) CL2021003557A1 (ar)
CO (1) CO2021017142A2 (ar)
CR (1) CR20210662A (ar)
EC (1) ECSP22003596A (ar)
IL (1) IL289575A (ar)
JO (1) JOP20210331A1 (ar)
MA (1) MA56451A (ar)
MX (1) MX2021015742A (ar)
PE (1) PE20220137A1 (ar)
PH (1) PH12021553286A1 (ar)
TW (1) TW202116779A (ar)
WO (1) WO2021001423A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor
WO2021000297A1 (en) 2019-07-03 2021-01-07 Merck Sharp & Dohme Corp. Compounds and methods of use thereof as antibacterial agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026700A (en) 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5252581A (en) 1992-07-20 1993-10-12 Hoechst-Roussel Pharmaceuticals Inc. Substituted aminothienopyridines, pharmaceutical composition and use
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DK0743853T3 (da) 1994-02-08 2001-07-16 Nps Pharma Inc Forbindelser, der er aktive ved et nyt sted på receptorstyrede calciumkanaler, og som er nyttige til behandling af neurologiske tilstande og sygdomme
WO1997046511A1 (en) 1996-06-07 1997-12-11 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1998056752A1 (en) 1997-06-11 1998-12-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
AU2011223976B2 (en) * 2010-03-04 2015-05-21 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor

Also Published As

Publication number Publication date
EP3994141A1 (en) 2022-05-11
IL289575A (en) 2022-03-01
TW202116779A (zh) 2021-05-01
KR20220029568A (ko) 2022-03-08
CL2021003557A1 (es) 2022-08-19
CN114008054A (zh) 2022-02-01
AU2020299992A1 (en) 2022-02-24
ECSP22003596A (es) 2022-02-25
WO2021001423A1 (en) 2021-01-07
US11466027B2 (en) 2022-10-11
CA3144304A1 (en) 2021-01-07
MA56451A (fr) 2022-05-11
PE20220137A1 (es) 2022-01-27
BR112021003928A2 (pt) 2021-05-18
AR119340A1 (es) 2021-12-09
CR20210662A (es) 2022-03-02
MX2021015742A (es) 2022-01-27
JP2022539197A (ja) 2022-09-07
CO2021017142A2 (es) 2022-01-17
PH12021553286A1 (en) 2022-08-01
US20210002292A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
EA201001371A1 (ru) Конденсированные пиримидиноновые соединения как модуляторы trpv3
EA201991553A1 (ru) (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды
BR112018013827A2 (pt) moduladores de 5?-nucleotidase, ecto e uso dos mesmos
MX2020013853A (es) Compuestos innovadores.
MX2022000961A (es) Inhibidores triciclicos de kars dependientes de akr1c3.
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
EA201991898A1 (ru) Двойные ингибиторы magl и faah
EA202091428A1 (ru) Замещенные амиды ii пирролидина
EA202090414A1 (ru) Соединения и их применение
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
EA201000675A1 (ru) Производные хромана как модуляторы trpv3
JOP20210332A1 (ar) عقاقير أولية لمعدلات المستقبل nmda
EA202091429A1 (ru) Замещенные амиды i пирролидина
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
JOP20210091A1 (ar) مشتقات أريل سلفونيل بيرول كربوكساميد على هيئة عوامل تنشيط قناة بوتاسيوم Kv3
JOP20210331A1 (ar) مُعَدِّلات مُستقبِل نمدا (nmda)
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2025006978A (es) Compuestos heterociclicos y usos de los mismos
EA202091524A1 (ru) Ингибиторы рецептора, активируемого протеазой 2
WO2022129047A3 (en) Modulators of the nmda receptor